Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesNovel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicidesPharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designMembrane-Active Sequences within gp41 Membrane Proximal External Region (MPER) Modulate MPER-Containing Peptidyl Fusion Inhibitor Activity and the Biosynthesis of HIV-1 Structural ProteinsEnfuvirtide: the first HIV fusion inhibitor.Antibody polyspecificity and neutralization of HIV-1: a hypothesisA rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicityAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocketImmunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS PatientsAnti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.Genetic Strategies for HIV Treatment and Prevention
P2860
Q27489000-88DDDED8-59B6-4D4E-B7E5-9A343766814FQ34055847-9E8D5BC4-89E7-4889-9BF7-921183EDB782Q34351993-AAA873E2-76AD-420C-B8B9-DD16C565EFDAQ35563298-3239298F-D286-4D34-92A6-DFA8C0CD35ADQ35729956-3E70FBA3-856E-4580-9520-4C0C8C153D92Q36082073-B49E2119-D38F-48E3-B6E4-01BEEE08A46BQ36487151-0245F4A0-FDFE-4ADF-AB65-7FAA77C3431CQ36558535-1BA2DE4C-6298-453F-A1B9-DE14D3C21182Q36600380-A2C9FFBF-2D31-4E23-90D7-014FC7DB6F5BQ38076321-22783B83-AF82-44FF-AE96-62CFCE5170CFQ38659433-AEAE958A-946D-42CE-8DEF-D92237DA2545Q40671956-CF23AF07-3291-436F-BDCF-F296F5BFD581Q40721814-96438D02-75B7-4F0D-AEAC-93A94E04C262Q58604627-604423AA-04EC-4314-A7D0-443A26E250BE
P2860
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Enfuvirtide (T-20) cross-react ...... cacy or safety of enfuvirtide.
@en
type
label
Enfuvirtide (T-20) cross-react ...... cacy or safety of enfuvirtide.
@en
prefLabel
Enfuvirtide (T-20) cross-react ...... cacy or safety of enfuvirtide.
@en
P2093
P50
P356
P1476
Enfuvirtide (T-20) cross-react ...... cacy or safety of enfuvirtide.
@en
P2093
Jacques Reynes
John Delehanty
Keith Henry
Mark Nelson
Miklos Salgo
Ralph DeMasi
Sharon Walmsley
P304
P356
10.1086/379810
P407
P577
2003-12-05T00:00:00Z